Abstract
The elucidation of the structure of somatostatin (GH release-inhibiting factor — SRIF) (Brazeau et al., 1973) and the demonstration that it is effective in inhibiting insulin and glucagon release by direct effects on the pancreas (Koerker et al., 1974) has resulted in a number of attempts to develop a long-acting preparation for potential clinical use. The duration of action of SRIF is limited to 5–10 minutes after intravenous administration (Brazeau et al., 1973) and to a maximum of 20–30 minutes after subcutaneous injection (Brazeau et al., 1974a; Martin, 1974) in the rat. Similar findings are reported in primates, including man.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
